Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.40 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

bohai pharmaceuticals group (BOPH) Snapshot

Open
$0.40
Previous Close
$0.40
Day High
$0.40
Day Low
$0.40
52 Week High
05/28/14 - $1.95
52 Week Low
03/26/15 - $0.31
Market Cap
7.8M
Average Volume 10 Days
3.5K
EPS TTM
$1.11
Shares Outstanding
19.5M
EX-Date
--
P/E TM
0.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for BOHAI PHARMACEUTICALS GROUP (BOPH)

Related News

No related news articles were found.

bohai pharmaceuticals group (BOPH) Related Businessweek News

No Related Businessweek News Found

bohai pharmaceuticals group (BOPH) Details

Bohai Pharmaceuticals Group, Inc., through its subsidiaries, engages in the production, manufacture, and distribution of herbal pharmaceuticals based on traditional Chinese medicine in the People’s Republic of China. It produces seven varieties of approved traditional Chinese herbal medicines comprising four prescription drugs and three over the counter products in seven delivery systems, including tablets, granules, capsules, formulations, concentrated powder, tincture, and medicinal wine for addressing rheumatoid arthritis, viral infections, gynecological diseases, cardio vascular issues, and respiratory diseases. The company’s products include Lung Nourishing syrup to moisten the lung and relieve coughs; Tongbi capsules to promote blood circulation and relieve swelling and pain; Tongbi tablets to regulate and fortify the blood promote blood circulation and relieve swelling pain; Zhuangyuanshenhailong medicinal wine to promote kidney function; and BazhenYimu cream for menstruation conditioning. Its products also comprise Fangfengtongsheng granules to treat cold, fever, headache, constipation, measles, and eczema; and Zhengxintai capsules to improve kidney function and treat coronary artery disease and angina. The company sells its products through hospitals, local pharmacies, and retail drug store chains. Bohai Pharmaceuticals Group, Inc. is headquartered in Yantai, China.

660 Employees
Last Reported Date: 10/21/14

bohai pharmaceuticals group (BOPH) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $77.5K
Compensation as of Fiscal Year 2014.

bohai pharmaceuticals group (BOPH) Key Developments

Bohai Pharmaceuticals Group, Inc. announced delayed annual 10-K filing

On 09/29/2014, Bohai Pharmaceuticals Group, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Bohai Pharmaceuticals Group, Inc. Announces Change of Auditors

Effective September 15, 2014, Bohai Pharmaceuticals Group, Inc. dismissed its independent registered public accounting firm, Marcum Bernstein & Pinchuk LLP (Marcum) effective immediately. The dismissal was approved by the Board of Directors of the company. Effective September 15, 2014, the company engaged Parker Randall CF (H.K.) CPA Limited (Parker) as the company's independent registered public accountant.

Bohai Pharmaceuticals Group, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2014

Bohai Pharmaceuticals Group, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2014. For the quarter, the company reported net revenues of $39,722,126 against $34,786,624 a year ago. Income from operations was $5,770,780 against $4,650,363 a year ago. Income before provision for income taxes was $5,437,402 against $4,196,087 a year ago. Net income was $3,928,011 or $0.19 per diluted share against $3,159,206 or $0.15 per diluted share a year ago. The increase in Bohai's third fiscal quarter net revenues compared to the same period a year ago was primarily due to an 11% increase in revenues contributed by the company's three leading TCM products: Lung Nourishing Syrup, and Tongbi Capsules and Tongbi Tablets for treatment of arthritis, which together accounted for over 96% of the company's net revenues in both the current fiscal year quarter and first nine-month period. The increase in the company's net income was attributable mostly to an increase in total gross profit of $3,729,763, offset by an increase in operating expenses of $2,609,346 for this year compared to the same period a year ago. For the nine months period, the company reported net revenues of $129,284,445 against $111,067,950 a year ago. Income from operations was $25,902,589 against $19,962,821 a year ago. Income before provision for income taxes was $24,393,703 against $19,790,160 a year ago. Net income was $18,024,773 or $0.85 per diluted share against $14,813,455 or $0.71 per diluted share a year ago. Bohai's improvement in fiscal 2014 nine month net Revenue was due primarily to a net increase in revenues of 18% from the above three products. The increase in the company's net income during the first nine months of fiscal 2014 compared to the same period a year ago was attributable mostly to an increase in total gross profit of $14,435,545, offset by an increase in operating expenses of $8,495,777.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BOPH:US $0.40 USD 0.00

BOPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BOPH.
View Industry Companies
 

Industry Analysis

BOPH

Industry Average

Valuation BOPH Industry Range
Price/Earnings 0.3x
Price/Sales 0.0x
Price/Book 0.1x
Price/Cash Flow 0.3x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOHAI PHARMACEUTICALS GROUP, please visit www.bohaipharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.